PL2806886T3 - Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach - Google Patents
Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanachInfo
- Publication number
- PL2806886T3 PL2806886T3 PL13700911T PL13700911T PL2806886T3 PL 2806886 T3 PL2806886 T3 PL 2806886T3 PL 13700911 T PL13700911 T PL 13700911T PL 13700911 T PL13700911 T PL 13700911T PL 2806886 T3 PL2806886 T3 PL 2806886T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions based
- protein compositions
- semifluorinated alkanes
- stabilised protein
- stabilised
- Prior art date
Links
- 150000001335 aliphatic alkanes Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21001—Chymotrypsin (3.4.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12152159 | 2012-01-23 | ||
| EP13700911.4A EP2806886B1 (en) | 2012-01-23 | 2013-01-22 | Stabilised protein compositions based on semifluorinated alkanes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2806886T3 true PL2806886T3 (pl) | 2017-08-31 |
Family
ID=47598843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13700911T PL2806886T3 (pl) | 2012-01-23 | 2013-01-22 | Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9757460B2 (enExample) |
| EP (1) | EP2806886B1 (enExample) |
| JP (1) | JP6084987B2 (enExample) |
| KR (1) | KR101989648B1 (enExample) |
| CN (1) | CN104066442B (enExample) |
| AU (1) | AU2013211645B2 (enExample) |
| BR (1) | BR112014017719A8 (enExample) |
| CA (1) | CA2862974C (enExample) |
| DK (1) | DK2806886T3 (enExample) |
| ES (1) | ES2625538T3 (enExample) |
| MX (1) | MX361681B (enExample) |
| PL (1) | PL2806886T3 (enExample) |
| PT (1) | PT2806886T (enExample) |
| WO (1) | WO2013110621A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
| PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
| AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| CA2918419C (en) * | 2013-07-23 | 2022-05-03 | Novaliq Gmbh | Stabilized antibody compositions |
| CN106455563A (zh) * | 2014-03-03 | 2017-02-22 | 安可视觉公司 | 硫辛酸胆碱酯组合物及使用方法 |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| WO2018054932A1 (en) | 2016-09-22 | 2018-03-29 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| CN109906085B (zh) | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| WO2018202835A1 (en) | 2017-05-05 | 2018-11-08 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| AU2019345929B2 (en) | 2018-09-27 | 2022-02-03 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
| CA3112504A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| MY206642A (en) | 2018-10-12 | 2024-12-30 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| AU2020340561A1 (en) | 2019-09-06 | 2022-03-31 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
| JP7761562B2 (ja) * | 2019-11-27 | 2025-10-28 | ノバリック ゲーエムベーハー | 非水性溶媒で懸濁されたタンパク質粒子を含む懸濁製剤 |
| CN115487305A (zh) * | 2022-09-21 | 2022-12-20 | 江苏君隽生物科技有限公司 | 一种用于递送活性药物成分的液体组合物 |
| WO2025133214A1 (en) | 2023-12-21 | 2025-06-26 | Novaliq Gmbh | Ophthalmic polypeptide compositions for the treatment of posterior eye disorders |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
| US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
| JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
| US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
| DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| US6224887B1 (en) | 1998-02-09 | 2001-05-01 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| WO2000045790A2 (en) | 1999-02-08 | 2000-08-10 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
| US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| US20030027833A1 (en) | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
| PT1423102E (pt) | 2001-09-04 | 2008-02-25 | Trommsdorff Arzneimittel | Emplastro para o tratamento de disfunções e perturbações o crescimento da unha |
| WO2003099258A1 (de) | 2002-05-24 | 2003-12-04 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Tropfbares ophthalmisches gelpräparat mit diclofenamid und timolol |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US20050075497A1 (en) | 2003-06-20 | 2005-04-07 | Ferdinand Utz | Hydrocolloids and process therefor |
| MXPA06002163A (es) | 2003-08-25 | 2006-05-22 | Foamix Ltd | Espuma farmaceutica de penetracion. |
| US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
| US20050175541A1 (en) | 2003-11-19 | 2005-08-11 | Lanza Gregory M. | Enhanced drug delivery |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| CA2563544A1 (en) | 2004-04-19 | 2005-10-27 | Centre National De La Recherche Scientifique (C.N.R.S.) | Lung surfactant supplements |
| JP2008501806A (ja) | 2004-06-08 | 2008-01-24 | オキュラリス ファーマ， インコーポレイテッド | 疎水性眼用組成物および使用方法 |
| KR20070040381A (ko) | 2004-07-01 | 2007-04-16 | 셰펜스 아이 리써치 | 눈의 장애 및 상태를 치료하는 조성물 및 방법 |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
| AU2006310113A1 (en) | 2005-08-05 | 2007-05-10 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
| DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
| DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| PL2110126T3 (pl) * | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
| US20100189765A1 (en) | 2008-11-26 | 2010-07-29 | Erickson Signe R | Implantable ocular drug delivery device and methods |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| WO2010146536A1 (en) * | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| US9012503B2 (en) | 2009-06-25 | 2015-04-21 | Lion Corporation | Ophthalmic composition |
| JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
| RU2532027C2 (ru) | 2009-07-24 | 2014-10-27 | Мика Фарма Гезельшафт Фюр Ди Энтвиклюнг Унд Фермарктунг Фармацойтишер Продукте Мбх | Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки |
| EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| CA2792517C (en) | 2010-03-09 | 2020-03-24 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations |
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| MX353154B (es) | 2011-01-04 | 2017-12-20 | Novaliq Gmbh | Emulsiones de aceite/agua que comprenden alcanos semifluorados. |
| EP2714008B1 (en) | 2011-05-25 | 2016-12-14 | Novaliq GmbH | Pharmaceutical composition for administration to nails |
| PL2714010T3 (pl) | 2011-05-25 | 2017-08-31 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
| AU2013211645B2 (en) | 2012-01-23 | 2017-06-15 | Novaliq Gmbh | Stabilised protein compositions based on semifluorinated alkanes |
| CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| CA2918419C (en) | 2013-07-23 | 2022-05-03 | Novaliq Gmbh | Stabilized antibody compositions |
| EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
-
2013
- 2013-01-22 AU AU2013211645A patent/AU2013211645B2/en active Active
- 2013-01-22 KR KR1020147019633A patent/KR101989648B1/ko active Active
- 2013-01-22 CN CN201380006417.2A patent/CN104066442B/zh active Active
- 2013-01-22 WO PCT/EP2013/051163 patent/WO2013110621A1/en not_active Ceased
- 2013-01-22 PT PT137009114T patent/PT2806886T/pt unknown
- 2013-01-22 EP EP13700911.4A patent/EP2806886B1/en active Active
- 2013-01-22 BR BR112014017719A patent/BR112014017719A8/pt not_active Application Discontinuation
- 2013-01-22 PL PL13700911T patent/PL2806886T3/pl unknown
- 2013-01-22 ES ES13700911.4T patent/ES2625538T3/es active Active
- 2013-01-22 US US14/373,877 patent/US9757460B2/en not_active Ceased
- 2013-01-22 DK DK13700911.4T patent/DK2806886T3/en active
- 2013-01-22 CA CA2862974A patent/CA2862974C/en active Active
- 2013-01-22 JP JP2014552660A patent/JP6084987B2/ja active Active
- 2013-01-22 MX MX2014008929A patent/MX361681B/es active IP Right Grant
- 2013-06-22 US US17/155,058 patent/USRE49758E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR101989648B1 (ko) | 2019-06-14 |
| DK2806886T3 (en) | 2017-06-06 |
| EP2806886B1 (en) | 2017-03-01 |
| US20140369993A1 (en) | 2014-12-18 |
| JP2015504082A (ja) | 2015-02-05 |
| USRE49758E1 (en) | 2023-12-19 |
| JP6084987B2 (ja) | 2017-02-22 |
| BR112014017719A2 (enExample) | 2017-06-20 |
| WO2013110621A1 (en) | 2013-08-01 |
| PT2806886T (pt) | 2017-03-24 |
| AU2013211645B2 (en) | 2017-06-15 |
| BR112014017719A8 (pt) | 2017-07-11 |
| KR20140125353A (ko) | 2014-10-28 |
| CN104066442A (zh) | 2014-09-24 |
| MX2014008929A (es) | 2015-06-02 |
| MX361681B (es) | 2018-12-13 |
| EP2806886A1 (en) | 2014-12-03 |
| ES2625538T3 (es) | 2017-07-19 |
| CA2862974A1 (en) | 2013-08-01 |
| US9757460B2 (en) | 2017-09-12 |
| CA2862974C (en) | 2021-11-16 |
| AU2013211645A1 (en) | 2014-07-17 |
| CN104066442B (zh) | 2018-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2806886T3 (pl) | Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach | |
| EP2857033A4 (en) | PEPTIDE WITH SKIN PERMEATION | |
| ZA201503594B (en) | Pharmaceutical compositions | |
| IL236304A0 (en) | Formulations for diclofenac | |
| EP2914662A4 (en) | CURABLE COMPOSITIONS | |
| DK2825039T3 (en) | Injectable ibuprofen formulation | |
| IL239395A0 (en) | Diclofenac preparation | |
| GB2506114B (en) | Boot | |
| SG11201500475TA (en) | Tack screw | |
| GB201201287D0 (en) | Compositions | |
| GB201200555D0 (en) | Peptide | |
| LT2908828T (lt) | Laktacijos stimuliatoriaus kompozicijos fosfatidilserino pagrindu | |
| PL2851083T3 (pl) | Kompozycja białkowa odporna na sterylizację promieniowaniem | |
| IL217807A0 (en) | Therapeutic compositions | |
| GB2500029B (en) | Curable compositions | |
| EP2831172A4 (en) | CURABLE COMPOSITIONS | |
| GB201211153D0 (en) | Pharmaceutical compositions | |
| EP2891663A4 (en) | PEPTIDE DERIVED FROM PSF1 | |
| IL238075A0 (en) | pharmaceutical preparations | |
| GB201211247D0 (en) | Improved formulation | |
| GB201219234D0 (en) | Pharmaceutical compositions | |
| GB201213303D0 (en) | Pharmaceutical compositions | |
| GB201221414D0 (en) | Trans-locating peptide | |
| GB201204810D0 (en) | Pharmaceutical compositions | |
| PH32012000407S1 (en) | Conventional combine |